Serotonin-dopamine interaction and its relevance to schizophrenia

American Journal of Psychiatry

Volumn 153, Issue 4, 1996, Pages 466-476

  Kapur, Shitij ^a   Remington, Gary ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; CYPROHEPTADINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; MIANSERIN; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE; RITANSERIN; SEROTONIN; SEROTONIN 1 ANTAGONIST; SEROTONIN 2 ANTAGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SETOPERONE;

CATALEPSY; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEUROBIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SYMPTOMATOLOGY;

EID: 0029988896     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.153.4.466     Document Type: Review

References (140)

1. Gerlach J, Peacock L: New antipsychotics: the present status. Int Clin Psychopharmacol 1995; 10:39-48
2. Breier A: Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res 1995; 14:187-202
3. Roth BL, Meltzer HY: The role of serotonin in schizophrenia, in Psychopharmacology: The Fourth Generation of Progress: An Official Publication of the American College of Neuropsychopharmacology. Edited by Bloom FE, Kupfer DJ. New York, Raven Press, 1995, pp 1215-1228
4. Le Moal M: Mesocorticolimbic dopaminergic neurons: functional and regulatory roles. Ibid, pp 283-294
5. Chiodo LA, Freeman AS, Bunney BS: Dopamine autoreceptor signal transduction and regulation. Ibid, pp 221-226
6. Roth RH, Elsworrh JD: Biochemical pharmacology of midbrain dopamine neurons. Ibid, pp 227-244
7. Jacobs BL, Azmitia EC: Structure and function of the brain serotonin system. Physiol Rev 1992; 72:165-229
8. Dubovsky SL, Thomas M: Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiatry 1995; 56: 38-48
9. Pazos A, Probst A, Palacios JM: Serotonin receptors in the human brain, IV:autoradiographic mapping of serotonin-2 receptors. Neuroscience 1987; 21:123-139
10. 1A receptors: pharmacological, biochemical, functional, and regulatory properties. Ann NY Acad Sci 1990; 600:114-129
11. Fibiger HC, Miller JJ: An anatomical and electrophysiological investigation of the serotonergic projection from the dorsal raphe nucleus to the substantia nigra in the rat. Neuroscience 1977; 2:975-987
12. Olpe HR, Koella WP: The response of striatal cells upon stimulation of the dorsal and median raphe nuclei. Brain Res 1977; 122:357-360
13. Nedergaard S, Bolam JP, Greenfield SA: Facilitation of a dendritic calcium conductance by 5-hydroxytryptamine in the substantia nigra. Nature 1988; 333:174-177
14. van der Kooy D, Hattori T: Dorsal raphe cells with collateral projections to the caudate-putamen and substantia nigra: a fluorescent retrograde double labeling study in the rat. Brain Res 1980; 186:1-7
15. Dray A, Davies J, Oakley NR, Tongroach P, Vellucci S: The dorsal and medial raphe projections to the substantia nigra in the rat: electrophysiological, biochemical and behavioural observations. Brain Res 1978; 151:431-442
16. Kelland MD, Freeman AS, Chiodo LA: Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J Pharmacol Exp Ther 1990; 253:803-811
17. James TA, Starr MS: Rotational behaviour elicited by 5-HT in the rat: evidence for an inhibitory role of 5-HT in the substantia nigra and corpus striatum. J Pharm Pharmacol 1980; 32:196-200
18. Giambalvo CT, Snodgrass SR: Biochemical and behavioral effects of serotonin neurotoxins on the nigrostriatal dopamine system: comparison of injection sites. Brain Res 1978; 152:555-566
19. Milson JA, Pycock CJ: Effects of drugs acting on cerebral 5-hydroxytryptamine mechanisms on dopamine-dependent turning behaviour in mice. Br J Pharmacol 1976; 56:77-85
20. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology (Berl) 1989; 98:45-50
21. 1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Arch Pharmacol 1993; 347:353-362
22. 1 receptor. Eur J Pharmacol 1988; 157:173-181
23. Ternaux JP, Hery F, Bourgoin S, Adrien J, Glowinski J, Hamon M: The topographical distribution of serotonergic terminals in the neostriatum of the rat and the caudate nucleus of the cat. Brain Res 1977; 121:311-326
24. Miller JJ, Richardson TI., Fibiger HC, McLennan H: Anatomical and electrophysiological identification of a projection from the mesencephalic raphe to the caudate-putamen in the rat. Brain Res 1975; 97:133-136
25. Pickel VM, Sesack SR: Electron microscopy of central dopamine systems, in Psychopharmacology: The Fourth Generation of Progress: An Official Publication of the American College of Neuropsychopharmacology. Edited by Bloom FE, Kupfer DJ. New York, Raven Press, 1995, pp 257-268
26. Soghomonian JJ, Descarries L, Watkins KC: Serotonin innervation in adult rat neostriatum, II: ultrastructural features: a radioautographic and immunocytochemical study. Brain Res 1989; 481:67-86
27. Tork I: Anatomy of the serotonergic system. Ann NY Acad Sci 1990; 600:9-34
28. Davies J, Tongroach P: Neuropharmacological studies on the nigro-striatal and raphe-striatal system in the rat. Eur J Pharmacol 1978; 51:91-100
29. Williams J, Davies JA: The involvement of 5-hydroxytryptamine in the release of dendritic dopamine from slices of rat subsrantia nigra. J Pharm Pharmacol 1983; 35:734-737
30. Hetev L, Drescher K: Influence of antipsychotics on presynaptic receptors modulating the release of dopamine in synaptosomes of the nucleus accumbens of rats. Neuropharmacology 1986; 25:1103-1109
31. Waldmeier PC, Delini-Stula AA: Serotonin-dopamine interactions in the nigrostriatal system. Eur J Pharmacol 1979; 55:363-373
32. 2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from rat brain striatal slices. Eur J Pharmacol 1988; 153:89-95
33. Ennis C, Kemp JD, Cox B: Characterisation of inhibitory 5-hydroxytryptamine receptors that modulate dopamine release in the striatum. J Neurochem 1981; 36:1515-1520
34. 3H]dopamine by serotonin from superfused rat striatal slices. Neurosci Lett 1982; 28:205-209
35. Andrews DW, Patrick RL, Barchas JD: The effects of 5 hydroxytryptophan and 5-hydroxytryptamine on dopamine synthesis and release in rat brain striatal synaptosomes. J Neurochem 1978; 30:465-470
36. Rokosz-Pelc A, Antkiewicz-Michaluk L, Vetulani J: 5-Hydroxytryptaminc-like properties of m-chlorophenylpiperazine: comparison with quipazine. J Pharm Pharmacol 1980; 32:220-222
37. Kostowski W, Gumulka W, Cxlonkowski A: Reduced cataleptogenic effects of some neuroleptics in rats with lesioned midbrain raphe and treated with p-chlorophenylalanine. Brain Res 1972; 48:443-446
38. 2 antagonists modulates the effects of D-2 dopamine receptor blockade. J Pharmacol ExpTher 1990; 253:1162-1170
39. de Belleroche JS, Bradford HF: Presynaptic control of the synthesis and release of dopamine from striatal synaptosomes: a comparison between the effects of 5-hydroxytryptamine, acetylcholine, and glutamate. J Neurochem 1980; 35:1227-1234
40. Spampinato U, Esposito E, Samanin R: Serotonin agonists reduce dopamine synthesis in the striatum only when the impulse flow of nigro-striatal neurons is intact. J Neurochem 1985; 45: 980-982
41. Baldessarini RJ, Marsh E: Fluoxetine and side effects. Arch Gen Psychiatry 1990; 47:191-192
42. Baldessarini RJ, Marsh ER, Kula NS: Interactions of fluoxetine with metabolism of dopamine and serotonin in rat brain regions. Brain Res 1992; 579:152-156
43. Dewey SL, Smith GS, Logan J, Alexoff D, Ding YS, King P, Pappas N, Brodie JD, Ashby CR Jr: Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 1995; 15:821-829
44. Dray A, Gonye TJ, Oakley NR, Tanner T: Evidence for the existence of a raphe projection to the substantia nigra in rat. Brain Res 1976; 113:45-57
45. 3-mediated increase in dopamine transmission (abstract). Neuropsychopharmacology 1994; 10(3S, part II):208S
46. 2 receptors in the rat medial prefrontal cortex. J Pharmacol Exp Ther 1990; 252:171-178
47. Gillet G, Ammor S, Fillion G: Serotonin inhibits acetylcholine release from rat striatum slices: evidence for a presynaptic receptor-mediated effect. J Neurochem 1985; 45:1687-1691
48. Dewey SL, Smith GS, Logan J, Brodie JD: Modulation of central cholinergic activity by GABA and serotonin: PET studies with 11C-benztropine in primates. Neuropsychopharmacology 1993; 8:371-376
49. Dewey SL, Smith GS, Logan J, Brodie JD, Simkowitz P, MacGregor RR, Fowler JS, Volkow ND, Wolf AP: Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc Natl Acad Sci USA 1993; 90:11816-11820
50. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544
51. Sanberg PR: Haloperidol-induced catalepsy is mediated by post synaptic dopamine receptors. Nature 1980; 284:472-473
52. Carter CJ, Pycock CJ: A study of the sites of interaction between dopamine and 5-hydroxytryptamine for the production of fluphenazine-induced catalepsy. Naunyn Schmiedcbcrgs Arch Pharmacol 1978; 304:135-139
53. Fuenmayor LD, Vogt M: The influence of cerebral 5-hydroxytryptamine on catalepsy induced by brain amine depleting neuroleptics or by cholinomimctics. Br J Pharmacol 1979; 67: 309-318
54. Costall B, Fortune DH, Naylor RJ, Mardsen CD, Pycock C: Serotonergic involvement with neuroleptic catalepsy. Neuropharmacology 1975; 14:859-868
55. Hicks PB: The effect of Serotonergic agents on haloperidol-induced catalepsy. Life Sci 1990; 47:1609-1615
56. Bethany S, Neal-Beliveau JN, Lucki J, Lucki I: Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 1993; 265:207-217
57. A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 1988; 27:515-518
58. Wadenberg ML: Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. J Neural Transm Gen Sect 1992; 89:49-59
59. Casey DE: Extrapyramidal syndromes: primate models as predictors of clinical response (abstract). Neuropsychopharmacology 1994; 10(3S, part I):370S
60. 2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction. Psychopharmacology (Berl) 1989; 97:456-461
61. Maj J, Sarnek J, Klimek V, Rawlow A: On the anticataleptic action of cyproheptadine. Pharmacol Biochem Behav 1976; 5: 201-205
62. Balsara JJ, Jadhav JH, Chandorkar AG: Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology (Berl) 1979; 62:67-69
63. Yamaguchi K, Nabeshima T, Kameyama T: Potentiation of phencyclidine-induced dopamine-dependent behaviors in rats after pretreatments with serotonin depletors. J Pharmacobiodyn 1986; 9:479-89
64. Baldessarini RJ, Amatruda TT, Griffith FF, Gerson S: Differential effects of serotonin on turning and sterotypy induced by apomorphine. Brain Res 1975; 93:158-163
65. Arnt J, Hyttel J, Bach-Lauritsen T: Further studies of the mechanism behind scopolamine-induced reversal of antistereotypic and cataleptogenic effects of neuroleptics in rats. Acta Pharmacol Toxicol (Copenh) 1986; 59:319-324
66. Korsgaard S, Gerlach J, Christensson E: Behavioral aspects of serotonin-dopamine interaction in the monkey. Eur J Pharmacol 1985; 118:245-252
67. Povlsen UJ, Noring U, Laursen AL, Korsgaard S, Gerlach J: Effects of serotonergic and anticholinergic drugs in haloperidol-induced dystonia in Cebus monkeys. Clin Neuropharmacol 1986; 9:84-90
68. Casey DE: Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates. Psychopharmacol Bull 1989; 25:457-459
69. 2-receptor antagonists can attenuate submaximal haloperidol-induced catalepsy in rats. Schizophr Res 1995; 15:153-154
70. Ceulemans DL, Gelders YG, Hoppenbrouwers ML, Reynjens AJ, Janssen PA: Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology (Berl) 1985; 85:329-332
71. 2 receptor blocker. Drug Development Res 1986; 8: 205-211
72. Gelders YG: Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br J Psychiatry 1989; 155:33-36
73. 2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 1990; 13:500-506
74. 2 antagonist ritanserin. Psychopharmacol Bull 1990; 26:373-376
75. Miller CH, Hummer M, Pycha R, Fleischhacker WW: The effect of ritanserin on treatment-resistant neuroleptic induced akathisia: case reports. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16:247-251
76. 2 antagonist, on Parkinsonian rest tremor. Curr Ther Res 1987; 41:298-300
77. Bouchard RH, Pourcher E, Filteau MJ, Baruch P: Dose-related modulation of DA dependent motor behavior by ritanserin (RIT) in idiopathic Parkinson's disease (IPD) (abstract). Neuropsychopharmacology 1994; 10(3S, part II):210S
78. 2 receptor antagonist, on Parkinson's disease. Clin Exp Neurol 1992; 29:277-282
79. Silver H, Blacker M, Weller MP, Lerer B: Treatment of chronic schizophrenia with cyproheptadine. Biol Psychiatry 1989; 25: 502-504
80. Korsgaard S, Friis T: Effects of mianserin in neuroleptic-induced parkinsonism. Psychopharmacology (Berl) 1986; 88:109-111
81. Hamilton MS, Opler LA: Akathisia, suicidality, and fluoxetine. J Clin Psychiatry 1992; 53:401-406
82. Klee B, Kronig MH: Case report of probable sertraline-induced akathisia (letter). Am J Psychiatry 1993; 150:986-987
83. Lipinski JF Jr, Mallya G, Zimmerman P, Pope HG Jr: Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989; 50:339-342
84. Coulter DM, Pillans PI: Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1995; 152:122-125
85. Arya DK: Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br J Psychiatry 1994; 165:728-733
86. Steur EN: Increase of Parkinson disability after fluoxetine medication. Neurology 1993; 43:211-213
87. Choo V: Paroxetine and extrapyramidal reactions (letter). Lancet 1993; 341:624
88. Rogue P, Danion Jean-M: Animal models of schizophrenia (abstract). Neuropsychopharmacology 1994; 10(3S, part I):292S
89. Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J: Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 1992; 49:959-965
90. Andreasen NC, Nopoulos P, Schultz S, Miller D, Gupta S, Swayze V, Flaum M: Positive and negative symptoms of schizophrenia: past, present, and future. Acta Psychiatr Scand Suppl 1994; 384:51-59
91. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RS: Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 1992; 160:179-186
92. Weinberger DR, Berman KF: Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia. Schizophr Bull 1988; 14:157-168
93. Deutch AY: The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm Suppl 1992; 36:61-89
94. Davis KL, Kahn RS, Ko G, Davidson M: Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148:1474-1486
95. Weinberger DR, Lipska BK: Cortical maldevelopment, antipsychotic drugs, and schizophrenia: a search for common ground. Schizophr Res 1995; 16:87-110
96. Rao ML, Moller HJ: Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment: a review. Neuropsychobiology 1994; 30: 160-172
97. Owens DCG: The pharmacology of negative and affective symptoms in psychosis (abstract). Neuropsychopharmacology 1994; 10(3S, part I):151S
98. Moghaddam B, Bunney BS: Acute effects of typical and atypical antipsychotic drugs on the release of dopaminc from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 1990; 54:1755-1760
99. Moghaddam B: Preferential activation of cortical dopamine neurotransmission by clozapine: functional significance. J Clin Psychiatry 1994; 55:27-29
100. Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH: Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology (Berl) 1994; 115: 147-156
101. 2 receptor and alpha 1-adrenoreceptor antagonism. J Clin Psychopharmacol 1995; 15(Feb suppl 1):11S-18S; correction, 15(2):154
102. 2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol 1995; 273:273-279
103. Mantz J, Godbout R, Tassin JP, Glowinski J, Thierry AM: Inhibition of spontaneous and evoked unit activity in the rat medial prefrontal cortex by mesencephalic raphe nuclei. Brain Res 1990; 524:22-30
104. 1c antagonist, and negative symptoms in schizophrenia: a placebo-controlled double-blind trial. Br J Psychiatry 1993; 163:451-455
105. Silver H, Nassar A: Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry 1992; 31:698-704
106. Spina E, Dedomenico P, Ruello C, Longobardo N, Gitto C, Ancione M, Dirosa AE, Caputi AP: Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 1994; 9:281-285
107. Goff DC, Midha KK, Saridsegal O, Hubbard JW, Amico E: A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berl) 1995; 117:417-423
108. Moller HJ, van Praag HM, Aufdembrinke B, Bailey P, Barnes TR, Beck J, Bentsen H, Eich FX, Farrow L, Fleischhacker WW: Negative symptoms in schizophrenia: considerations for clinical trials. Psychopharmacology (Berl) 1994; 115:221-228
109. Schooler NR: Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits. Acta Psychiatr Scand 1994; 89:21-26
110. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
111. Casey DE: Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl) 1989; 99(suppl):S47-S53
112. Shopsin B, Klein H, Aaronsom M, Collora M: Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison. Arch Gen Psychiatry 1979; 36:657-664
113. Claghorn J, Honigfeld G, Abuzzahab FS Sr, Wang R, Steinbook R, Tuason V, Klerman G: The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7:377-384
114. 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25:390-392
115. 2 pKi values. J Pharmacol Exp Ther 1989; 251: 238-246
116. Crouzel C, Guillaume M, Barre L, Lemaire C, Pike VW: Ligands and tracers for PF.T studies of the 5-HT system - current status. Int J Rad Appl Instrum [B] 1992; 19:857-870
117. Farde L, Nordstrom AL: PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry 1992:30-33
118. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995; 152:1444-1449
119. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40
120. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825-835
121. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, Heylen S: Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 85:295-305
122. Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I: Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993; 88:395-402
123. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995;57:PL103-PL107
124. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995; 152:173-178
125. 2 antagonism and EPS: is there & causal connection? Psychopharmacology (Berl) (in press)
126. McEvoy JP, Hogarty GE, Steingard S: Optimal dose of neuroleptic in acute schizophrenia: a controlled study of neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991; 48:739-745
127. Stone CK, Garver DL, Griffith J, Hirschowitz J, Bennett J: Further evidence of a dose-response threshold for haloperidol in psychosis. Am J Psychiatry 1995; 152:1210-1212
128. Janicak PG, Javaid JI, Sharma RP, Leach A, Dowd S, Davis JM: A double-blind randomized study of three haloperidol plasma levels for acute psychosis, in New Research Program and Abstracts, 148th Annual Meeting of the American Psychiatric Association. Washington, DC, APA, 1995
129. 2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 1995; 15(Feb suppl 1):19S-23S
130. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. AmJ Psychiatry 1994; 151:20-26
131. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH: Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49:345-353
132. Muller-Spahn F: Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol (International Risperidone Research Group). Clin Neuropharmacol 1992; 15(suppl 1, part A):90A-91A
133. Borison R, Pathiraja AP, Diamond BI, Meibach RC: Risperidone: clinical saftey and efficacy in schizophrenia. Psychopharmacol Bull 1992; 28:213-218
134. Miller DD, Perry PJ, Cadoret RJ, Andreasen NC: Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 1994; 35:8-15
135. Moller HJ: The negative component in schizophrenia. Acta Psychiatr Scand 1995; 91:11-14
136. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstcin P, Kane JM: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151:1744-1752
137. 2 receptors. Psychopharmacology (Berl) 1993; 112:540-554
138. Schotte A, Janssen PF, Megens AA, Leysen JE: Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res 1993; 631:191-202
139. Yeomans JS: Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology 1995; 12:3-16
140. 2-antagonism: a crucial factor for the treatment of schizophrenia (abstract). Neuropsychopharmacology 1994; 10(3S, part I):467S